Full Press Release Details
Therapeutics Announces FDA Clearance of Investigational New Drug
to Initiate Phase 1 Clinical Trial of Decoy20 in Solid Tumors
YORK (May 19, 2022) - Indaptus Therapeutics, Inc. (Nasdaq: INDP) ("Indaptus" or the "Company"), today announced
that the U.S. Food and Drug Administration (FDA) has cleared the Company's Investigational New Drug (IND) application for a Phase
1 clinical trial in patients with advanced solid tumors where currently approved therapies have failed. The Company plans to initiate
the clinical trial in the second half of 2022.
are excited to begin our first in human study of Decoy20, as there is still a significant unmet medical need for patients with advanced
solid tumors. This is an important milestone for Indaptus, which brings us one step closer to our goal of demonstrating the utility of
a multi-targeted and antigen-agnostic, systemic immunotherapy that primes and activates both innate and adaptive anti-tumor immune responses,"
said Jeffrey Meckler, Chief Executive Officer of Indaptus.
remodel and inhibit systemic immune responses and Indaptus' Decoy technology is unique in its ability to mobilize both innate and
adaptive anti-tumor immune pathways with systemic administration in pre-clinical tumor models, while at the same time not inducing sustained
hallmarks of cytokine release syndromes in pre-clinical toxicology studies," said Dr. Michael Newman, Founder and Chief Scientific
Officer of Indaptus.
trial is a Phase 1, open-label dose escalation and expansion study evaluating the safety, tolerability and preliminary efficacy of Decoy20
in patients with advanced solid tumors. We look forward to demonstrating the safety profile of Decoy20 and developing an effective, novel
therapy for cancers unresponsive to existing approved therapies," continued Mr. Meckler.
Phase 1 study is designed to evaluate the safety, tolerability, and preliminary efficacy of Decoy 20 and will follow a 3+3 design of
dose-escalation cohorts. The study protocol allows for exploration of additional dosing regimens, including continuous weekly administration
after initial safety has been established. Decoy20 has the potential to treat a wide range of solid tumors including hepatocellular,
colorectal and pancreatic carcinomas.
Indaptus Therapeutics
Therapeutics has evolved from more than a century of immunotherapy advances. The Company's approach is based on the hypothesis
that efficient activation of both innate and adaptive immune cells and associated anti-tumor and anti-viral immune responses will require
a multi-targeted package of immune system activating signals that can be administered safely intravenously. Indaptus' patented
technology is composed of single strains of attenuated and killed, non-pathogenic, Gram-negative bacteria, with reduced i.v. toxicity,
but largely uncompromised ability to prime or activate many of the cellular components of innate and adaptive immunity. Decoy20 represents
an antigen-agnostic technology that has produced significant single agent activity against metastatic pancreatic and orthotopic colorectal
carcinomas, single agent eradication of established, antigen-expressing breast carcinoma, as well as combination-mediated eradication
of established hepatocellular carcinomas and non-Hodgkin's lymphomas in standard pre-clinical models, including syngeneic mouse
tumors and human tumor xenografts. Tumor eradication has been observed with Decoy products in combination with anti-PD-1 checkpoint therapy,
low-dose chemotherapy or an approved targeted antibody. Combination-based tumor eradication produces innate and adaptive immunological
memory, involves activation of both innate and adaptive immune cells and is associated with induction of innate and adaptive immune pathways
in tumors after only one i.v. dose of Decoy product, with associated "cold" to "hot" tumor inflammation signature
transition. IND-enabling toxicology studies have demonstrated safe i.v. administration, with no sustained induction of hallmarks of cytokine
release syndromes, possibly due to passive targeting to liver, spleen and tumor, followed by rapid elimination of the product. Indaptus
products have also produced significant single agent activity against chronic hepatitis B virus (HBV) and chronic human immunodeficiency
virus (HIV) infections in pre-clinical models.
press release contains forward-looking statements with the meaning of the Private Securities Litigation Reform Act. These include statements
regarding management's expectations, beliefs and intentions regarding, among other things, our product development efforts, business,
financial condition, results of operations, strategies, plans and prospects. Forward-looking statements can be identified by the use
of forward-looking words such as "believe", "expect", "intend", "plan", "may",
"should", "could", "might", "seek", "target", "will", "project",
"forecast", "continue" or "anticipate" or their negatives or variations of these words or other comparable
words or by the fact that these statements do not relate strictly to historical matters. Forward-looking statements relate to anticipated
or expected events, activities, trends or results as of the date they are made. Because forward-looking statements relate to matters
that have not yet occurred, these statements are inherently subject to risks and uncertainties that could cause our actual results to
differ materially from any future results expressed or implied by the forward-looking statements. Many factors could cause actual activities
or results to differ materially from the activities and results anticipated in forward-looking statements, including, but not limited
to, the following: our plans to develop and potentially commercialize its technology, the timing and cost of our planned investigational
new drug application and any clinical trials, the completion and receiving favorable results in any clinical trials, Indaptus'
ability to obtain and maintain regulatory approval of any product candidate, our ability to protect and maintain its intellectual property
and licensing arrangements, our ability to develop, manufacture and commercialize its product candidates, the risk of product liability
claims, the availability of reimbursement, the influence of extensive and costly government regulation, and our estimates regarding future
revenue, expenses capital requirements and the need for additional financing. More detailed information about the risks and uncertainties
affecting us is contained under the heading "Risk Factors" included in our most recent Annual Report on Form 10-K filed with
the SEC on March 21, 2022, and in other filings that we have made and may make with the Securities and Exchange Commission in the future.
All forward-looking statements speak only as of the date of this press release and are expressly qualified in their entirety by the cautionary
statements included in this press release. We undertake no obligation to update or revise forward-looking statements to reflect events
or circumstances that arise after the date made or to reflect the occurrence of unanticipated events, except as required by applicable